Home | Health | Diabetes
Elixir Pharmaceuticals, Inc., announced that it has completed enrollment in its final pivotal phase III clinical study of mitiglinide for the treatment of patients with type 2 diabetes. The study is expected to be completed during the third quarter of 2008, with data available shortly thereafter. The results from this study will supplement the existing clinical database of more than 4,000 patients to form the basis of the Company's anticipated new drug application (NDA) submissions to the FDA in early 2009 for Glinsuna™ (mitiglinide) and a fixed combination product, Metgluna™, combining metformin and Glinsuna. "We are pleased to meet this important milestone in the development of these exciting product candidates," stated Dr. Paul Martha, Chief Medical Officer and SVP, Clinical Development and Regulatory Affairs. "We believe Metgluna could become an important new treatment option for the more than five million metformin patients who will eventually require additional glucose control, and Glinsuna would offer a new treatment option for physicians and patients who prefer the dosing flexibility offered by the single agent." Elixir's clinical study has enrolled more than 300 patients across 60 sites in the U.S. and is designed to evaluate the efficacy and safety of mitiglinide in combination with metformin in patients whose blood sugar is not adequately controlled by metformin alone. This study is expected to confirm results from a previously completed trial in Australia which demonstrated that the combination produced improved (lowered) A1c (HbA1c) levels versus metformin alone. In previous clinical studies, Glinsuna has been shown to significantly lower patients' levels of hemoglobin HbA1c by mimicking the natural response to glucose by producing a rapid and brief burst of insulin to coincide with the rise in glucose levels following meals. William K. Heiden, Elixir's President and Chief Executive Officer stated, "Completing enrollment in this final phase III mitiglinide study moves us one step closer to providing important new therapy options to physicians and their type II diabetic patients. It also moves Elixir one step closer to achieving our goal of having commercial products fund the development of our blockbuster-potential ghrelin and SIR T products for the treatment of metabolic disease." About Type 2 Diabetes Type 2 diabetes is a chronic metabolic disorder characterized by high blood sugar caused by defective insulin secretion, resistance to insulin action, or a combination of both. It is a serious and debilitating disease, affecting more than 20 million Americans in the U.S. alone, 30% of whom are estimated to be undiagnosed. While there has been significant progress in the treatment of type 2 diabetes in the last decade, there is still an enormous unmet medical need worldwide. Approximately half of people diagnosed with type 2 diabetes have not achieved adequate blood sugar level control, as measured by HbA1c. HbA1c is a measure of average blood sugar over time and takes into account the baseline level of sugar (fasting plasma glucose) and the rises that occur after a meal (post-meal glucose). The American Diabetes Association recommends that patients with type 2 diabetes achieve a target HbA1c level of < 7%. Type 2 diabetes increases the risk for many serious complications, particularly heart disease, blindness, nerve damage and kidney damage, all of which can be reduced by tightly controlling the level of blood sugar.
Article Source: http://www.share.citynewslive.com
Please Rate this Article
5 out of 54 out of 53 out of 52 out of 51 out of 5
Not yet Rated
